REPLIGEN CORP
- CIK: 0000730272
- EIN: 04-2729386
- Business address: 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, Massachusetts, 02453
Information
Mailing address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, Delaware, 02453Phone
7814499560State location
MassachusettsState of incorporation
DelawareFiscal year end
December 31SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)Filings
N/A
About REPLIGEN CORP
REPLIGEN CORP (CIK: 0000730272) is an American company incorporated in the state of Massachusetts. Head office is located at 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, Massachusetts, 02453. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). REPLIGEN CORP is a public company and trade via Over-The-Counter (OTC).Ownership
| Owner | Filings | Transaction Date | Type of Owner |
|---|---|---|---|
| Madaus Martin D | 0001310268 | Feb-06-2023 | director |
| Konstantinov Konstantin | 0001774649 | May-26-2022 | director |
| Gebski Christine | 0001849585 | Feb-25-2021 | officer: See Remarks |
| Bylund James | 0001849642 | Feb-25-2021 | officer: SVP, Global Operations & IT |
| EGLINTON MANNER CARRIE | 0001696776 | Jun-11-2020 | director |
| Mhatre Rohin | 0001798735 | Mar-01-2020 | director |
| COOPER GLENN L MD | 0001046351 | May-15-2019 | director |
| MUIR GLENN P | 0001181190 | May-15-2019 | director |
| DAWES KAREN A | 0001261506 | May-15-2019 | director |
| Cox John | 0001498428 | May-15-2019 | director |
| KURIYEL RALF | 0001733143 | Dec-18-2018 | officer: Senior VP, R&D |
| Hunt Anthony | 0001606030 | Sep-10-2018 | director, officer: Chief Executive Officer |
| BARTHELEMY NICOLAS | 0001283576 | Aug-29-2018 | director |
| Snodgres Jon | 0001613498 | Aug-28-2018 | officer: CFO |
| EDDLEMAN ROY T | 0001270264 | Aug-01-2017 | 10 percent owner |
| RUSCHE JAMES R | 0001241031 | Dec-31-2016 | officer: SENIOR VICE PRESIDENT |
| RYAN THOMAS F JR | 0001263366 | Dec-31-2016 | director |
| Lieber Jonathan I | 0001350090 | Sep-20-2012 | officer: CFO |
| GRIFFITH MICHAEL A | 0001241821 | Apr-11-2012 | director |
| Spurr Robert | 0001543795 | Mar-12-2012 | officer: Chief Commercial. Officer |
| Hall Michael | 0001543852 | Mar-12-2012 | officer: Chief Medical Officer |
| BIOTECHNOLOGY VALUE FUND L P | 0000918923 | May-15-2009 | 10 percent owner, other: Group Member |
| BVF PARTNERS L P/IL | 0001055947 | May-15-2009 | 10 percent owner, other: Group Member |
| BVF INC/IL | 0001056807 | May-15-2009 | 10 percent owner, other: Group Member |
| BIOTECHNOLOGY VALUE FUND II LP | 0001102444 | May-15-2009 | 10 percent owner, other: Group Member |
| BVF INVESTMENTS LLC | 0001132245 | May-15-2009 | 10 percent owner, other: Group Member |
| LAMPERT MARK N | 0001233840 | May-15-2009 | 10 percent owner, other: Group Member |
| Benjamin Howard | 0001393547 | Jan-05-2009 | other: VP Business Development |
| Goldberg Alfred Lewis | 0001438947 | Jul-01-2008 | director |
| Kelly William J | 0001431114 | Mar-31-2008 | officer: Vice President |
| Henry Earl Webb | 0001421891 | Dec-12-2007 | director |
| MUEHL DANIEL W | 0001283569 | Jan-12-2006 | officer: CFO |
| Harris Timothy Scott | 0001349176 | Jan-05-2006 | other: VP Corporate Development |
| DAY BARBARA BURNIM | 0001241028 | Apr-30-2004 | officer: Vice President |
| HERLIHY WALTER C | 0001241029 | Apr-30-2004 | director, officer: PRESIDENT, CEO |
| WITT DANIEL P | 0001241030 | Apr-30-2004 | officer: Vice President |
| LANDY HAL | 0001241034 | Apr-30-2004 | officer: Vice President |
| Whitehouse Laura | 0001289428 | Apr-30-2004 | officer: Vice President |
| MILLER G WILLIAM | 0001115875 | Sep-10-2003 | director |
| HENNESSEY ROBERT J | 0001234374 | Sep-10-2003 | director |
| RICH ALEXANDER | 0001236445 | Sep-10-2003 | director |
| SCHIMMEL PAUL | 0001236447 | Sep-10-2003 | director |
Stock Chart
Coming soon!
Jobs
Coming soon!
Recent SEC Filings
Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by REPLIGEN CORP
| Filings | Format | Description | Filed/Effective | File/Film Number |
|---|---|---|---|---|
| ARS | Document | Annual report to security holders Acc-no: 0001193125-25-073463 (34 Act) Size: KB |
Apr-04-2025 | 25815115 |
| DEFA14A | Document | Additional definitive proxy solicitation materials Acc-no: 0001193125-25-073456 (34 Act) Size: KB |
Apr-04-2025 | 25815068 |
| DEF 14A | Document | Definitive proxy statements Acc-no: 0000950170-25-051141 (34 Act) Size: KB |
Apr-04-2025 | 25814947 |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-048942 ( Act) Size: 0 KB |
Apr-02-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-042471 ( Act) Size: 0 KB |
Mar-20-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-042026 ( Act) Size: 0 KB |
Mar-19-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-041119 ( Act) Size: 0 KB |
Mar-18-2025 | |
| PRE 14A | Document | Preliminary proxy statement not related to a contested matter or merger/acquisition Acc-no: 0000950170-25-040321 (34 Act) Size: KB |
Mar-17-2025 | 25744866 |
| 144 | Document | Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-25-002056 (33 Act) Size: 0 KB |
Mar-17-2025 | 25742738 |
| 10-K | Document | Annual report pursuant to section 13 and 15(d) Acc-no: 0000950170-25-038999 (34 Act) Size: KB |
Mar-14-2025 | 25737275 |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-031593 ( Act) Size: 0 KB |
Mar-04-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-031591 ( Act) Size: 0 KB |
Mar-04-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-031572 ( Act) Size: 0 KB |
Mar-04-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-031569 ( Act) Size: 0 KB |
Mar-04-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-031547 ( Act) Size: 0 KB |
Mar-04-2025 | |
| NT 10-K | Document | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT Acc-no: 0001193125-25-044191 (34 Act) Size: KB |
Mar-03-2025 | 25698802 |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-030097 ( Act) Size: 0 KB |
Feb-28-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-030080 ( Act) Size: 0 KB |
Feb-28-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-030066 ( Act) Size: 0 KB |
Feb-28-2025 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000950170-25-030063 ( Act) Size: 0 KB |
Feb-28-2025 |
Recent 20 filings. View all REPLIGEN CORP filings
Reviews
Jean Bishop
Very good communication and delivery made within the timeframe I was advised of
Ryan Storey
Huge help thank you for your help .. y'all make it so much easier
Samuel Ejimofor
It's being easier working on the website. And I recommend, it's a great website
Frequently Asked Questions
Tags:
- REPLIGEN CORP overview
- REPLIGEN CORP job
- REPLIGEN CORP stock
- REPLIGEN CORP ownership
- REPLIGEN CORP CEO
- REPLIGEN CORP documents
Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.
Orther Companies
Maze Therapeutics, Inc.
Update: Jan 08, 2025
Inhibrx Biosciences, Inc.
Update: Apr 26, 2024
CG Oncology, Inc.
Update: Jan 03, 2024
Iris Parent Holding Corp.
Update: Nov 09, 2023
Kyverna Therapeutics, Inc.
Update: Nov 08, 2023
Sequoia Vaccines, Inc.
Update: Nov 07, 2023
Latest News
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Charges Crypto Company SafeMoon and its Executive Team for...
© 2022 